KNSA 21.21 (+1.87%)
BMG5269C1010BiotechnologyBiotechnology

Kiniksa Pharmaceuticals (KNSA) Financial Metrics

This table shows a selected set of financial data points of Kiniksa Pharmaceuticals (KNSA). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 0.2 0 87.26 1.23B 0.03 270.26M 13.17M -22.86M 14.08M 107.95M
2022 2.64 0 5.67 1.04B 0.53 220.18M 5.7M 12.18M 183.36M 122.72M
2021 -2.3 0 -5.11 807.15M -0.54 38.54M -146.71M -154.28M -157.92M 122.47M
2020 -2.61 0 -6.77 1.09B -0.53 0 -136.82M -154.96M -161.38M 114.04M
2019 -2.99 0 -3.69 597.79M -0.56 0 -161.57M -169.96M -161.87M 46.93M
2018 -3.49 0 -8.04 829.99M -0.56 0 -86.3M -103.16M -103.23M 71.98M
2017 -2.74 0 0 0 -1.25 0 -50.29M -64.84M -64.87M 45.56M
2016 -0.74 0 0 0 0 0 -21.87M -23.92M -23.97M 55.97M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.